Increasing buprenorphine access for patients with chronic pain : a quality improvement initiative
© The Author(s) 2023. Published by Oxford University Press on behalf of the American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
OBJECTIVE: Buprenorphine is effective for chronic pain and safer than full-agonist opioids; however, limited education about and support for buprenorphine can result in under-prescribing in primary care and reduced access in specialty pain clinics. The purpose of this quality improvement initiative was to optimize and evaluate procedures for transferring patients stable on buprenorphine for chronic pain from a specialty pain clinic back to primary care.
SETTING: Eight primary care clinics within a Veterans Health Administration health care system.
METHODS: A standard operating procedure for facilitated transfer of prescribing was developed after a needs assessment and was introduced during an educational session with primary care providers, and providers completed a survey assessing attitudes about buprenorphine prescribing. Success of the initiative was measured through the number of patients transferred back to primary care over the course of 18 months.
RESULTS: Survey results indicated that primary care providers with previous experience prescribing buprenorphine were more likely to view buprenorphine prescribing for pain as within the scope of their practice and to endorse feeling comfortable managing a buprenorphine regimen. Providers identified systemic and educational barriers to prescribing, and they identified ongoing support from specialty pain care and primary care as a facilitator of prescribing. Metrics suggested that the standard operating procedure was generally successful in transferring and retaining eligible patients in primary care.
CONCLUSION: This quality improvement initiative suggests that a facilitated transfer procedure can be useful in increasing buprenorphine prescribing for pain in primary care. Future efforts to increase primary care provider comfort and address systemic barriers to buprenorphine prescribing are needed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Pain medicine (Malden, Mass.) - 25(2024), 3 vom: 01. März, Seite 226-230 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wesolowicz, Danielle M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
40D3SCR4GZ |
|---|
| Anmerkungen: |
Date Completed 04.03.2024 Date Revised 04.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/pm/pnad140 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363402101 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363402101 | ||
| 003 | DE-627 | ||
| 005 | 20240304232004.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/pm/pnad140 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1316.xml |
| 035 | |a (DE-627)NLM363402101 | ||
| 035 | |a (NLM)37847654 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wesolowicz, Danielle M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Increasing buprenorphine access for patients with chronic pain |b a quality improvement initiative |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2024 | ||
| 500 | |a Date Revised 04.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of the American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a OBJECTIVE: Buprenorphine is effective for chronic pain and safer than full-agonist opioids; however, limited education about and support for buprenorphine can result in under-prescribing in primary care and reduced access in specialty pain clinics. The purpose of this quality improvement initiative was to optimize and evaluate procedures for transferring patients stable on buprenorphine for chronic pain from a specialty pain clinic back to primary care | ||
| 520 | |a SETTING: Eight primary care clinics within a Veterans Health Administration health care system | ||
| 520 | |a METHODS: A standard operating procedure for facilitated transfer of prescribing was developed after a needs assessment and was introduced during an educational session with primary care providers, and providers completed a survey assessing attitudes about buprenorphine prescribing. Success of the initiative was measured through the number of patients transferred back to primary care over the course of 18 months | ||
| 520 | |a RESULTS: Survey results indicated that primary care providers with previous experience prescribing buprenorphine were more likely to view buprenorphine prescribing for pain as within the scope of their practice and to endorse feeling comfortable managing a buprenorphine regimen. Providers identified systemic and educational barriers to prescribing, and they identified ongoing support from specialty pain care and primary care as a facilitator of prescribing. Metrics suggested that the standard operating procedure was generally successful in transferring and retaining eligible patients in primary care | ||
| 520 | |a CONCLUSION: This quality improvement initiative suggests that a facilitated transfer procedure can be useful in increasing buprenorphine prescribing for pain in primary care. Future efforts to increase primary care provider comfort and address systemic barriers to buprenorphine prescribing are needed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a buprenorphine | |
| 650 | 4 | |a chronic pain | |
| 650 | 4 | |a opioids | |
| 650 | 4 | |a pain management | |
| 650 | 4 | |a primary care | |
| 650 | 7 | |a Buprenorphine |2 NLM | |
| 650 | 7 | |a 40D3SCR4GZ |2 NLM | |
| 650 | 7 | |a Analgesics, Opioid |2 NLM | |
| 700 | 1 | |a Spelman, Juliette F |e verfasserin |4 aut | |
| 700 | 1 | |a Edmond, Sara N |e verfasserin |4 aut | |
| 700 | 1 | |a Schwartz, Amy R |e verfasserin |4 aut | |
| 700 | 1 | |a Kravetz, Jeffrey D |e verfasserin |4 aut | |
| 700 | 1 | |a Edens, Ellen L |e verfasserin |4 aut | |
| 700 | 1 | |a Becker, William C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pain medicine (Malden, Mass.) |d 2000 |g 25(2024), 3 vom: 01. März, Seite 226-230 |w (DE-627)NLM126305021 |x 1526-4637 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:3 |g day:01 |g month:03 |g pages:226-230 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/pm/pnad140 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 3 |b 01 |c 03 |h 226-230 | ||